AbCellera Biologics Inc. (ABCL) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
AbCellera (ABCL) Q1 2026: $655M Liquidity Anchors Push Toward $6B Menopause Market
May 12, 2026
-
AbCellera (ABCL) Q4 2025: Pipeline Expands to 4 Clinical Programs, $700M Liquidity Extends Runway
February 25, 2026
-
AbCellera (ABCL) Q3 2025: $680M Liquidity Anchors Clinical Pipeline Transition
November 07, 2025
-
AbCellera (ABCL) Q2 2025: $750M Liquidity Powers Clinical Pipeline Pivot
August 08, 2025
-
AbCellera (ABCL) Q1 2025: $43M R&D Spend Accelerates Clinical Pipeline Transition
July 05, 2025
-
AbCellera (ABCL) Q3 2024: $32M R&D Impairment Marks Pipeline Prioritization Pivot
November 04, 2024
-
AbCellera (ABCL) Q2 2024: Research Fee Revenue Falls 30% as Internal Pipeline Becomes Priority
August 06, 2024
-
AbCellera (ABCL) Q1 2024: $725M Liquidity Anchors Pipeline and Platform Buildout
May 07, 2024
-
AbCellera (ABCL) Q4 2023: Royalty Rate Rises to 4.3% as Internal Pipeline Drives Strategic Shift
February 20, 2024